HD-OPM Archive
Topics › Statins

PLANET trial: atorvastatin preferred over rosuvastatin in CKD (with July 2026 correction)

Louis Nervegna · Dec 06, 2025 · ♥ 9 reactions · 7 comments · original Facebook post
StatinsKidney health
AI summary & key facts

Louis shares a teaching card that atorvastatin is the preferred statin in chronic kidney disease, citing the PLANET trial comparing it with rosuvastatin. His later edit says the original text had a typo: the correct statement is that atorvastatin improved proteinuria but had no effect on eGFR.

Atorvastatin is the preferred statin in patients with chronic kidney disease, per the PLANET trial.

EDIT (July 2026) - The post below has a typo. The correct statement is that atorvastatin improved proteinuria, but had no effect on eGFR.

#ckdHD #atorvastatinHD #rosuvastatinHD #kidneysHD #statinskidneysHD

Research cited

✅✅ATORVASTATIN IS THE PREFERRED STATIN IN CKD PATIENTS

The most common cause of mortality in patients with CKD is cardiovascular, and therefore statins are recommended.

The PLANET (Prospective Evaluation of Proteinuria and Renal Function in Diabetic [and Nondiabetic] Patients With Progressive Renal Disease) trial showed that rosuvastatin was associated with decreased glomerular filtration rate (GFR) and increased proteinuria, whereas atorvastatin improved GFR and had no effect on proteinuria.

← newer: Location of the heart valves (anatomy image)older: Spanish post on polyphenols' health benefits across the life →